Drugs for Relapse Prevention of Alcoholism

245 Pages·2005·1.74 MB·English

by  Griffith Edwards (auth.)

(( 3. Umbruch 2.11.2004 ))
Milestones in Drug Therapy
MDT
Series Editors
Prof. Michael J. Parnham, PhD Prof. Dr. J. Bruinvels
Senior Scientific Advisor Sweelincklaan 75
PLIVA Research Institute Ltd NL-3723 JC Bilthoven
Prilaz baruna Filipovic´a 29 The Netherlands
HR-10000 Zagreb
Croatia
Drugs for Relapse
Prevention of Alcoholism
Edited by R. Spanagel and K.F. Mann
Birkhäuser Verlag
Basel · Boston · Berlin
Editors
Rainer Spanagel Karl F. Mann
Universität Heidelberg Klinik für Abhängiges Verhalten und
Abteilung für Psychopharmakologie Suchtmedizin
J5,Zentralinstitut für Seelische Gesundheit J5,Zentralinstitut für Seelische Gesundheit
68159 Mannheim 68159 Mannheim
Germany Germany
Advisory Board
J.C. Buckingham (Imperial College School of Medicine,London,UK)
R.J. Flower (The William Harvey Research Institute,London,UK)
G. Lambrecht (J.W. Goethe Universität,Frankfurt,Germany)
Library of Congress Cataloging-in-Publication Data
Bibliographic information published by Die Deutsche Bibliothek
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed biblio-
graphic data is available in the internet at http://dnb.ddb.de
ISBN 3-7643-0214-3 Birkhäuser Verlag,Basel - Boston - Berlin
The publisher and editor can give no guarantee for the information on drug dosage and administration
contained in this publication. The respective user must check its accuracy by consulting other sources
of reference in each individual case.
The use of registered names,trademarks etc. in this publication,even if not identified as such,does
not imply that they are exempt from the relevant protective laws and regulations or free for general
use.
This work is subject to copyright. All rights are reserved,whether the whole or part of the material is
concerned,specifically the rights of translation,reprinting,re-use of illustrations,recitation,broad-
casting,reproduction on microfilms or in other ways,and storage in data banks. For any kind of use,
permission of the copyright owner must be obtained.
©2005 Birkhäuser Verlag,P.O. Box 133,CH-4010 Basel,Switzerland
Part of Springer Science+Business Media
Printed on acid-free paper produced from chlorine-free pulp. TFC ∞
Cover illustration:((folgt))
Printed in Germany
ISBN 3-7643-0214-3
9 8 7 6 5 4 3 2 1 www. birkhauser.ch
V
Contents
List of contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XI
Griffith Edwards
History of prevention of relapse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Rainer Spanagel
How to measure relapse in animals . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Henry R. Kranzler and Howard Tennen
How to measure relapse in humans . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Dieter Ladewig and Ulrich von Bardeleben
Disulfiram (Antabuse®):the first medication to stop drinking . . . . . . 41
Michael S. Cowen
Naltrexone:preclinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Charles P. O’Brien,Helen M. Pettinati and David W. Oslin
Naltrexone:clinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Philippe De Witte,Daniel Bachteler and Rainer Spanagel
Acamprosate:preclinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Karl F. Mann
Acamprosate:clinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Anh Dzung Lê and Douglas R. Funk
Serotonergic compounds:preclinical data . . . . . . . . . . . . . . . . . . . . . 95
Bankole A. Johnson
Serotonergic compounds:clinical data . . . . . . . . . . . . . . . . . . . . . . . . 107
Petri Hyytiä
Opioidergic compounds:preclinical data . . . . . . . . . . . . . . . . . . . . . . 117
VI Contents
John David Sinclair
Second generation opioidergic compounds:clinical data . . . . . . . . . . 125
Friedbert Weiss
Dopaminergic compounds:preclinical data . . . . . . . . . . . . . . . . . . . . 135
Gerhard A. Wiesbeck
Dopaminergic compounds:clinical data . . . . . . . . . . . . . . . . . . . . . . 155
Mauro A.M. Carai,Roberta Agabio,Giovanni Addolorato,
Gian L. Gessa and Giancarlo Colombo
Baclofen:preclinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Giovanni Addolorato,Ludovico Abenavoli,Lorenzo Leggio,
Giosuè DeLorenzi,Anna Ferrulli,Fabio Caputo,Roberta Agabio,
Gian Luigi Gessa,Giancarlo Colombo and Giovanni Gasbarrini
Baclofen:clinical data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Mauro A.M. Carai,Carla Lobina,Gian Luigi Gessa and
Giancarlo Colombo
Cannabinoid receptor antagonists:a perspective . . . . . . . . . . . . . . . . 181
Markus Heilig and Todd E. Thiele
Neuropeptide Y antagonists:a perspective . . . . . . . . . . . . . . . . . . . . . 189
Daniel Bachteler and Rainer Spanagel
Glutamatergic compounds:a perspective . . . . . . . . . . . . . . . . . . . . . . 205
Rainer Spanagel and Karl F. Mann
Future perspectives on relapse prevention . . . . . . . . . . . . . . . . . . . . . 217
Appendix – Chemical structures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
VII
List of contributors
Ludovico Abenavoli, Institute of Internal Medicine, Catholic University,
Gemelli Hospital,L.go A. Gemelli 8,00168 Rome,Italy
Giovanni Addolorato, Institute of Internal Medicine, Catholic University,
Gemelli Hospital, L.go A. Gemelli 8, 00168 Rome, Italy; e-mail:
[email protected]
Roberta Agabio, Department of Neuroscience, University of Cagliari, Viale
Diaz 182,09126 Cagliari,Italy; e-mail:[email protected]
Daniel Bachteler, Department of Psychopharmacology, University of
Heidelberg, Central Institute of Mental Health (CIMH), J5, 68159
Mannheim,Germany; e-mail:[email protected]
Fabio Caputo, G. Fontana, Center for the Study and Treatment of Alcohol
Addiction, University of Bologna, Viale Risorgimento 2, 40136 Bologna,
Italy
Mauro A.M. Carai,Department of Neuroscience,University of Cagliari,Viale
Diaz 182,09126 Cagliari,Italy; e-mail:[email protected]
Giancarlo Colombo, C.N.R. Institute of Neuroscience, Section of Cagliari,
Viale Diaz 182,09126 Cagliari,Italy; e-mail:[email protected]
Michael S. Cowen, Howard Florey Institute, University of Melbourne, VIC
3010,Australia; e-mail:[email protected]
Giosuè deLorenzi,Institute of Internal Medicine,Catholic University,Gemelli
Hospital,L.go A. Gemelli 8,00168 Rome,Italy
Philippe De Witte,UCL – Biologie du Comportement,Place Croix du Sud,1
bte 10,1348 Louvain-la-Neuve,Belgium; e-mail:[email protected]
Griffith Edwards, National Addiction Centre, Institute of Psychiatry, 4
Windsor Walk,London SE 5AF,UK; e-mail:[email protected]
Anna Ferrulli, Institute of Internal Medicine, Catholic University, Gemelli
Hospital,L.go A. Gemelli 8,00168 Rome,Italy
Douglas R. Funk, Department of Neuroscience, Center for Addition and
Mental Health,Toronto,Ontario,Canada M5S 2S1
Giovanni Gasbarrini, Institute of Internal Medicine, Catholic University,
Gemelli Hospital, L.go A. Gemelli 8, 00168 Rome, Italy; e-mail:
[email protected]
Gian Luigi Gessa, Department of Neuroscience, University of Cagliari,
Cagliari; and C.N.R. Institute of Neuroscience, Viale Diaz 182, 09126
Cagliari,Italy; e-mail:[email protected]
Markus Heilig, Laboratory of Clinical and Translational Studies, National
Institute of Alcohol Abuse and Alcoholism,National Institiute of Health,10
Center Drive (10/1E5330), Bethesda, MD, 20892-1108, USA; e-mail:
VIII List of contributors
[email protected]
Petri Hyytiä, Department of Mental Health and Alcohol Research, National
Public Health Institute, POB 33, FI-00251 Helsinki, Finland; e-mail:
[email protected]
Bankole A. Johnson, South Texas Addiction Research & Technology Center,
Department of Psychiatry, The University of Texas Health Science Center
at San Antonio, 3939 Medical Drive, Suite 100, San Antonio, TX 78229-
3900,USA; e-mail:[email protected],and Departments of Psychiatric
Medicine and Neuroscience, University of Virginia, P.O. Box 800623,
Charlottesville, VA 22908-0623, USA; e-mail: bankolejohnson@
virginia.edu
Henry R. Kranzler, Department of Psychiatry, University of Connecticut
Health Center, Farmington, CT 06030-2103, USA; e-mail:
[email protected]
Dieter Ladewig, Department of Substance Use Disorders, Psychiatric
University Hospital, Wilhelm Klein-Strasse 27, 4025 Basel, Switzerland;
e-mail:[email protected]
Anh Dzung Lê,Department of Neuroscience,Center for Addiction and Mental
Health, Toronto, Ontario, Canada M5S 2S1; and Department of
Pharmacology and Psychiatry, University of Toronto, Toronto, Ontario,
Canada M5S 1A8; e-mail:[email protected]
Lorenzo Leggio, Institute of Internal Medicine, Catholic University, Gemelli
Hospital,L.go A. Gemelli 8,00168 Rome,Italy
Carla Lobina,Department of Neuroscience,University of Cagliari,Viale Diaz
182,09126 Cagliari,Italy
Karl F. Mann, Department of Addictive Behaviour and Addiction Medicine,
University of Heidelberg, Central Institute of Mental Health, J 5, 68159
Mannheim,Germany; e-mail:[email protected]
Charles P. O’Brien, University of Pennsylvania, Department of
Psychiatry/Philadelphia Veterans Affairs Medical Center, Treatment
Research Center, 3900 Chestnut Street, Philadelphia, PA 19104-6178,
USA; e-mail:[email protected]
David W. Oslin, University of Pennsylvania, Department of Psychiatry/
Philadelphia Veterans Affairs Medical Center, Treatment Research Center,
3900 Chestnut Street, Philadelphia, PA 19104-6178, USA; e-mail:
[email protected]
Helen M. Pettinati, University of Pennsylvania, Department of
Psychiatry/Philadelphia Veterans Affairs Medical Center, Treatment
Research Center, 3900 Chestnut Street, Philadelphia, PA 19104-6178,
USA; e-mail:[email protected]
John David Sinclair, Department of Mental Health and Alcohol Research,
National Public Health Institute (KTL), POB 33, Helsinki 00251, Finland;
e-mail:[email protected]
Rainer Spanagel, Department of Psychopharmacology, Central Institute of
Mental Health (CIMH), University of Heidelberg, J5, 68159 Mannheim,
List of contributors IX
Germany; e-mail:[email protected]
Howard Tennen, Department of Community Medicine and Health Care,
University of Connecticut Health Center, Farmington, CT 06030-2103,
USA; e-mail:[email protected]
Todd E. Thiele, Department of Psychology, University of North Carolina,
Davie Hall,CB 3270,Chapel Hill,NC 27599-3270,USA
Ulrich von Bardeleben, Psychiatrische Klinik Meiringen, 3860 Meiringen,
Switzerland; e-mail:[email protected]
Friedbert Weiss, Department of Neuropharmacology, The Scripps Research
Institute (CVN 15), 10550 North Torrey Pines Road, La Jolla, CA 92037,
USA; e-mail:[email protected]
Gerhard A. Wiesbeck, Department of Substance Use Disorders, Psychiatric
University Hospital, Wilhelm-Klein-Strasse 27, 4025 Basel, Switzerland;
e-mail:[email protected]